TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05487664

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Neruostimulation (tAN)
Description: The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Neruostimulation (tAN)
Description: The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Neruostimulation (tAN)
Description: The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Auricular Neruostimulation (tAN)
Description: The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Auricular Neruostimulation (tAN)
Description: The intervention we are studying is called transcutaneous auricular neurostimulation (tAN). tAN is simply electrical nerve stimulation administered at the ear which targets both the auricular branch of the vagus nerve (ABVN) and the auriculotemporal nerve (ATN, a branch of the trigeminal nerve).
Study: NCT06700148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCV4
Description: 1 dose of MCV4 on Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MPSV4
Description: 1 dose of MPSV4 on Day0
Study: NCT06715670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan
Description: Participant will receive 4 different single doses of zibotentan on Day 1 of each treatment period orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan
Description: Participant will receive 4 different single doses of zibotentan on Day 1 of each treatment period orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan
Description: Participant will receive 4 different single doses of zibotentan on Day 1 of each treatment period orally.
Study: NCT05499247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinQ Glow Bright Wonder Mask
Description: Mode of Usage:~Cleanse and dry face. Apply 1 tsp or 5g of the product. Apply with clean finger or brush to full face. Leave to dry for 15 minutes. Wipe with wet cotton or rinse with cool water.~Route of Administration: Topical
Study: NCT06379763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diaphragmatic breathing exercise
Description: 15-minute diaphragmatic breathing exercise from a semi-Fowler's position. Patients will be instructed to position one hand on the chest and the other on the belly, gradually inhaling deeply through the nose, moving from functional residual capacity to total lung capacity, and holding the breath for three seconds. Patients will be advised to relax their shoulders, maintain quiet upper chest movement, and allow the abdomen to slightly rise. Subsequently, patients will exhale slowly through the mouth for up to five seconds. Diaphragmatic breathing exercises will be organized into three sets lasting 15 minutes, with 3 minutes of active exercise and a 2-minute rest period between sets. During rest intervals, patients will be instructed to breathe normally. If individuals experience dizziness or discomfort, the session will stop.
Study: NCT06715670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zibotentan
Description: Participant will receive 4 different single doses of zibotentan on Day 1 of each treatment period orally.
Study: NCT06718686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin SSD 40 mg IR tablet
Description: Drug therapy vs placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug
Study: NCT06725069

Intervention type: OTHER
Intervention: Neuromuscular Electrical Stimulation
Description: NMES was performed using the Enraf Nonius Myomed 632X device. Both applications were performed 5 days/week for 4 weeks. NMES was performed with the patients in a sitting position and the affected arm resting on a table with the forearm supinated (Agonist group) / forearm pronated (Antagonist group). Surface electrodes (50x50 mm self-adhesive) were placed on the wrist and finger flexor/extensor muscle group. NMES parameters; Symmetric biphasic, pulse width 200 μs, on time 6 seconds (ramp up 1 second, ramp down 2 seconds), off time 12 seconds, stimulation intensity according to the patient's tolerance (not exceeding 90 mA), frequency 50 Hz and was adjusted to elicit contraction in the flexor and extensor muscles of the wrist and fingers.

Intervention type: OTHER
Intervention: Neuromuscular Electrical Stimulation
Description: NMES was performed using the Enraf Nonius Myomed 632X device. Both applications were performed 5 days/week for 4 weeks. NMES was performed with the patients in a sitting position and the affected arm resting on a table with the forearm supinated (Agonist group) / forearm pronated (Antagonist group). Surface electrodes (50x50 mm self-adhesive) were placed on the wrist and finger flexor/extensor muscle group. NMES parameters; Symmetric biphasic, pulse width 200 μs, on time 6 seconds (ramp up 1 second, ramp down 2 seconds), off time 12 seconds, stimulation intensity according to the patient's tolerance (not exceeding 90 mA), frequency 50 Hz and was adjusted to elicit contraction in the flexor and extensor muscles of the wrist and fingers.

Intervention type: OTHER
Intervention: Control (Standard treatment)
Description: In addition to conventional treatment, participants were included in an occupational rehabilitation program for 20 minutes to improve upper extremity functions.
Study: NCT06727604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMVT-1402
Description: 600 mg SC QW for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMVT-1402
Description: 600 mg SC QW for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMVT-1402
Description: 600 mg SC QW for 26 weeks followed by Placebo SC QW for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC QW for 52 weeks
Study: NCT06738121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infra-umbilical incision
Description: Traditional curvilinear infra-umbilical incision is used to repair the umbilical hernia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transumbilical incision
Description: The incision for the repair of the umbilical hernia will be carried through the umbilicus itself.
Study: NCT06743165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with ultrasound biofeedback
Description: Pelvic floor muscle training (PFMT) will be given to both groups with transabdominal US. PFMT will be applied by physiotherapists who have received training and supervision from physiotherapists who are experts in the field of pelvic floor US imaging and pelvic floor muscle training with US. Pelvic floor muscle training will be applied with a GE Brand LOGIQ P8 model transabdominal ultrasound (GE HealthCare) US device under the supervision of an expert physiotherapist. Parents and children will be informed about PFMT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training with ultrasound biofeedback
Description: Pelvic floor muscle training (PFMT) will be given to both groups with transabdominal US. PFMT will be applied by physiotherapists who have received training and supervision from physiotherapists who are experts in the field of pelvic floor US imaging and pelvic floor muscle training with US. Pelvic floor muscle training will be applied with a GE Brand LOGIQ P8 model transabdominal ultrasound (GE HealthCare) US device under the supervision of an expert physiotherapist. Parents and children will be informed about PFMT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilization exercise
Description: Dynamic neuromuscular exercises (DNS) involve the joint activation of the intrinsic muscle group of the spine, which includes the cervical flexors and extensors, diaphragm, transversus abdominis, multifidus and pelvic floor, which form the integrated spinal stabilization system. The application principles are joint centering, core stabilization - Integrated spinal stabilization system and stabilization function of the diaphragm. DNS training will be applied in three stages. Preparation for exercises, IAB regulation and application of exercises according to developmental kinesiology positions. Exercises will start with preparatory training. In preparatory training, stroking, brushing and tapping techniques will be taught and self-facilitation will be demonstrated in order to increase proprioceptive input to the lower extremity, upper extremity, trunk and pelvic region. Fascial mobilizations will be performed to the foot and hand regions.
Study: NCT06750692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure: Mirror therapy
Description: The first group of participants will receive a total of 20 sessions of upper extremity mirror therapy program, 5 sessions per week for 4 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Low Frequency rTMS Protocol
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) will be applied at an intensity of 100-110% of the resting motor threshold and low frequency (1 Hz) to the contralateral M1 upper extremity motor cortex region for a total of 20 sessions, 5 sessions per week for 4 weeks. rTMS application is planned to provide magnetic stimulation with the stimulator of the Magventure MagPro R30 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted hand therapy
Description: In the Robot Assisted Therapy group, a total of 20 sessions will be applied 5 days a week for 4 weeks using continuous passive range of motion, active assistive exercise and play therapy programs for hemiplegic upper extremities with AMADEO (Tyromotion Austria).
Study: NCT06750731

Intervention type: DEVICE
Intervention: Tappt
Description: Tappt is a web-based system designed to record participants medication taking behavior and bowel symptoms. Participants will be assigned smart labels for their specific vedolizumab regimen, which will be used by participants to record their vedolizumab use. Participants will be shipped smart labels to be affixed to an IV card for the first three infusions and for subsequent infusions or injections. At the time of a vedolizumab dose, participants will scan the smart label by tapping it with their mobile device to verify that they are taking the medication. Each day that vedolizumab is due, patients will receive a reminder through SMS message. If participants fail to scan the label at a given time (as expected by their specific medication regimen), they will receive an end of day text message reminder. Participants will also complete a patient reported outcome assessment at baseline, weekly for 6 weeks, and then monthly for the entire 22 weeks of the study triggered by the system.
Study: NCT06750900

Intervention type: OTHER
Intervention: NORMAL CONDITION
Description: They perform 3 lumbar extensions until the onset of pain without virtual reality

Intervention type: OTHER
Intervention: UNDERSTATED CONDITION
Description: They perform 3 lumbar extensions until the onset of pain using the virtual reality. In this condition, they feel that they are moving a 10%less than they are really moving.

Intervention type: OTHER
Intervention: OVERSTATED CONDITION
Description: They perform 3 lumbar extensions until the onset of pain using the virtual reality. In this condition, they feel that they are moving a 10% more than they are really moving.
Study: NCT06750861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: QL1706+AG
Study: NCT06755931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quilling set
Description: After the intervention group is determined in randomization, half an hour before the cardiac catheterization and angiography procedure, without premedication treatment, the researcher will be asked to choose 2 animal and plant figures, samples of which have been previously made, through a quilling set, in cooperation with the researcher. It will be done with the child in a 15-20 minute period, accompanied by the researcher, with 2 figures chosen by the child. With the opportunity for the child to choose the color and figure he/she wants, the child will be at the center of the work. The figure will be given as a gift to the child and the survey forms will be filled out again 5 minutes after the application, before the premedication treatment. In order to prevent bias in the research, the descriptive information form and fear and anxiety scales will be taken by the evaluation of three people: the researcher, the parent and the child.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Before the procedure, while the child is in the patient room, the details of the research will be explained, their consent will be obtained and the Introductory Information Form will be filled in by the parent, and the Fear Scale and State Anxiety Scale will be filled in by the child and the parent. After the control group is determined in randomization, the researcher will apply the posttest without premedication treatment half an hour before the cardiac catheterization and angiography procedure. No separate intervention will be applied. In accordance with ethical principles, after the procedure, 2 Quilling figures chosen by the control group and the child will be prepared with the help of the researcher, and the prepared figures will be gifted to the child.
Study: NCT06753955

Intervention type: DRUG
Group type: OTHER
Intervention: ART5803
Description: A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor.

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous immunoglobulin (IVIG)
Description: Administered as background treatment prior to the investigational product
Study: NCT06754930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1826
Description: SHR-1826 for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: SHR-1316 for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839
Description: SHR-9839 for injection.
Study: NCT04079179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: All groups will receive the same intervention. Cobimetinib will be given orally at a maximum dose of 60mg daily for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: All groups will receive the same intervention. Cobimetinib will be given orally at a maximum dose of 60mg daily for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: All groups will receive the same intervention. Cobimetinib will be given orally at a maximum dose of 60mg daily for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: All groups will receive the same intervention. Cobimetinib will be given orally at a maximum dose of 60mg daily for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
Study: NCT06575556

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac CT and MRI
Description: • Cardiac MRI Protocol~The cardiac MRI protocol will include cine imaging, aortic flow, and 3D navigator of the aorta. These sequences will be performed to assess aortic root dimensions, including aortic root, sinuses of Valsalva, and sinotubular junction and ascending aorta diameters.~• CT Aortography Protocol:~The CT aortography protocol will include non-contrast and contrast-enhanced CT imaging. The non-contrast images will be used for calcium scoring, while the contrast-enhanced images will be used to assess aortic root dimensions
Study: NCT05890274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AF and EKG Interpretation Project ECHO
Description: The AF and EKG Interpretation Project ECHO program is delivered via Zoom videoconferencing technology and includes 12, 1-hour long sessions that involve education on best practice management of AF for primary care providers. Each session includes an EKG challenge, case presentation by a participant, didactic presentation, and time for open Q\&A. Supplementary materials are made available to all participants.
Study: NCT06326554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual and in-person Symptom screening with Targeted Early Palliative care (STEP2)
Description: Study nurse will offer a palliative care clinic visit referral alongside usual cancer care to participants who report moderate to high symptom burden.
Study: NCT05835063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: We Chatt communication tool
Description: This arm involves the collaborative completion of a 2-page communication preferences document between a primary physician and an adolescent/young adult patient. Physicians will participate in a 1-hour training led by study principal investigator featuring didactic, multimedia, and experiential-based learning to support the facilitation of the WE CHATT intervention with patients.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual/standard care
Description: Usual/standard care will be provided. Physicians randomized to the control arm will not receive training in the WE CHATT communication intervention.
Study: NCT06576713

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Combiner whole genome and RNA sequencing
Description: High-throughput DNA and RNA sequencing
Study: NCT06503484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-computer interface
Description: Patients will be instructed to perform kinesthetic motor imagery of the affected upper extremity in response to a visual cue given by the BCI system. Before the training session, 15 motor imagery tasks without neurofeedback will be recorded to calibrate the average level of individual brain activation and determine the optimal channel within the ipsilesional M1 area as the localizer. During the training session, patients will be instructed to do motor imagery. The level of HbO will be extracted from the ipsilesional M1 as the signal intensity. The signal intensity will be quantified as the percent signal change relative to the baseline. Once the signal intensity reaches the predefined individual threshold, patients will receive neurofeedback in the form of visual feedback, presented in a digital mirror therapy system (Masquer M2, SharpSight Limited, Hong Kong SAR). The visual feedback guides the patients to perform observational imitation using the affected upper limb.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham brain-computer interface
Description: In the sham BCI group, patients will wear identical equipment to the BCI group. However, the visual feedback presented in the digital mirror therapy system will be given based on the brain activity of another participant in the BCI group, i.e., yoked sham neurofeedback. Like the BCI group, patients will be instructed to use kinesthetic motor imagery and imitate the movement when receiving visual feedback. Patients will perform 15 motor imagery tasks in the calibration session, followed by 90 motor imagery tasks in the training session. The training tasks and duration will be the same as the BCI group, therefore patients will be blinded to their group allocation.
Study: NCT06450392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: 100 mg/mL (manufactured concentration) local TXA injection in the orbit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid in NaCl,Iso-Os 1,000 Mg/100 mL (10 Mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML)
Description: 1g IV TXA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline - injection
Description: 0.9% Normal Saline injection in the orbit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline - injection
Description: 0.9% Normal Saline injection in the orbit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline - intravenous
Description: 0.9% IV Normal Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline - intravenous
Description: 0.9% IV Normal Saline
Study: NCT04795934

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION
Description: LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION
Description: LAPAROSCOPIC PARAESOPHAGEAL HIATAL HERNIA REPAIR COMBINED WITH TRANSORAL INCISIONLESS FUNDOPLICATION VERSUS LAPAROSCOPIC NISSEN FUNDOPLICATION
Study: NCT06510270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 mg once daily
Description: Dapagliflozin 10 mg once daily will be given to all patients in symptomstic heart failure group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loop diuretics
Description: Loop diuretics (IV or orally) will be given to all patients in symptomatic heart failure group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)
Description: Treatment of associated co-morbidities will be given to both arms (group) such as anti-hypertensive (B blockers, ACIE, ARBS, CA channel blockers, Diuretics), oral hypoglycemic (Metformins, sulfonyl urea,.......)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatments of associated co-morbidities (e.g Anti-hypertensive, oral hypoglycemic)
Description: Treatment of associated co-morbidities will be given to both arms (group) such as anti-hypertensive (B blockers, ACIE, ARBS, CA channel blockers, Diuretics), oral hypoglycemic (Metformins, sulfonyl urea,.......)